Kornimate/medical-research-clean huggingface dataset:
effects of robot-assisted rehabilitation on upper extremity functions in chronic stroke

Conditions: Stroke; Upper Extremity Paresis

Summary: the most common problem caused by stroke is motor activity limitation that reduces muscle movement and mobility. but stroke can also lead to sensory and cognitive impairment. additionally, the ability to independently carry out activities of daily living and participate in social and community life is greatly reduced. up to 85% of stroke patients experience hemiparesis immediately after stroke, while 55% to 75% of survivors continue to experience reduced quality of life with motor impairments. it requires long-term physical rehabilitation to achieve functional recovery in the upper extremity, maximum independence and the highest possible quality of life. different methods can be used to achieve these results, but there is no clear evidence yet as to which treatment method gives the best results. scientific evidence shows that a multifactorial approach and high-intensity treatment accelerates the motor recovery of the upper extremities in stroke rehabilitation. passive and active upper extremity movements appear to increase motor recovery due to their effects on somatosensory input, motor planning, soft tissue properties and spasticity. in recent years, robotic devices have emerged that have been proven to improve the motor performance of the upper extremity in chronic stroke patients. there are also studies showing that robotic device-assisted upper extremity therapy can contribute to the development of sensorimotor skills in plegic patients. however, in the current literature, there is still a need for randomized controlled studies in this field. the aim of this study is to investigate the effects of robot-assisted therapy on upper extremity functions and daily living activities in the rehabilitation of chronic stroke patients. after the demographic data of the cases in both groups are obtained, evaluations will be made before the study. then, the study group will receive conventional physiotherapy in a single session of 45 minutes a day, 3 days a week for 4 weeks, and in addition robot-assisted therapy with the reogo upper extremity exoskeleton robot in a single session of 60 minutes a day, 5 days a week for 4 weeks. the control group will receive only conventional physiotherapy in a single session of 45 minutes a day, 3 days a week for 4 weeks. the initial evaluations will be repeated after the end of the treatment period.


Eligibility criteria:
inclusion criteria: * having had a single stroke * having had at least 6 months since the stroke * having hemiparesis/hemiplegia following the stroke * having mental health sufficient to meet all evaluation and treatment procedures in the study exclusion criteria: * having a history of disease other than stroke that affects the use of the upper extremity

Keywords: robotic rehabilitation chronic stroke upper limb activities of daily living
study to investigate skin conditions and patient assessment of las 41002 in the treatment of atopic eczema

Conditions: Atopic Eczema

Summary: the aim of the study is an intra-individual comparison of skin conditions in addition to a patient based assessment of product appearance in the topical treatment of atopic eczema.


Eligibility criteria:
inclusion criteria: * men and women aged 18 years or older; * two comparable treatment areas (difference in local scorad not greater than 3) on opposite extremities of 100 - 300 cm2 with at least one lesional region within each of these areas of ≥ 20 cm². clinical condition of atopic eczema mild to moderate defined by a local scorad of at least 5 with 1. erythema ≥ 2 2. lichenification ≥ 1 3. dryness ≥ 1 4. itching ≥ 1 * erlangen atopy score sum equal or higher than 10 points (3); * the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study; * female patients of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices \[iuds\], sexual abstinence or vasectomized partner; * written informed consent obtained exclusion criteria: * acne, suntan, eczema, hyperpigmentation or tattoos in the test areas; * dark-skinned persons whose skin color prevents ready assessment of skin reactions; * evidence of drug or alcohol abuse; * pregnancy or nursing; * uv-therapy within 6 weeks before first treatment; * symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before and during the study; * participation in the treatment phase of another clinical study within the last four weeks prior to the first administration of investigational drug in this study; * known allergic reactions to components of the study preparations, hypersensitivity against cetostearyl alcohol; * treatment with systemic or locally acting medications which might counter or influence the study aim (e.g. antihistamines or glucocorticosteroids) within two weeks before study day 1and throughout the study period (exception: asthma may be found in patients with atopic eczema, therefore inhalation with corticosteroids in patients with asthma accompanying atopic eczema will be allowed at a dose not exceeding 1 mg/day. the dosage should remain constant throughout the study period); * contraindications according to summary of product characteristics; * in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e.g. due to probable noncompliance or inability to understand the study and give adequately informed consent; * patient is institutionalized because of legal or regulatory order
neural stem cell preserving brain radiation therapy & stereotactic radiosurgery in patients with 1-6 brain metastases

Conditions: Lung Cancer; Breast Cancer; Prostate Cancer

Summary: for patients with 1-6 intraparenchymal brain metastases from various primary histologies (except for melanoma), stereotactic radiosurgery (administered upfront or concurrently) or complete surgical resection with neural stem cell (nsc)-preserving whole-brain radiotherapy (wbrt) results in improved neurocognitive profile over standard wbrt. the goal of this study is to assess feasibility of this treatment approach.

cancer patients (except patients with melanoma) with 1-6 brain metastases are randomized to receive standard whole brain radiation therapy or whole brain radiation therapy in a neural stem cell-preserving manner.

Eligibility criteria:
inclusion criteria: * histologically confirmed non-melanoma primary malignancy with 1-6 intraparenchymal brain metastases (or small cell lung cancer being considered for prophylactic brain irradiation (pbi) with no demonstrable intracranial lesions). * a diagnostic contrast-enhanced magnetic resonance imaging (mri) demonstrating the presence of 1-6 brain metastases performed within 4 weeks of registration. note: if small cell lung cancer primary and patient being considered for pbi, mri must demonstrate no intracranial lesions. * patients with totally resected intraparenchymal brain metastases; not all lesions need be resected if all other criteria are satisfied (no more than 6 total lesions) * the contrast-enhancing intraparenchymal brain tumor must be well circumscribed and must have maximum diameter of no more than 4 cm in any dimension on the enhanced scan. if multiple lesions are present and one lesion is at the maximum diameter, the other(s) must not exceed 3.0 cm in maximum diameter. * metastatic lesions must be distributed peripherally, that is, at least 0.5 cm lateral (outside) of the lateral ventricles and/or hippocampus bilaterally. posterior fossa metastatic lesions are allowed in the study. * age 18 years or older. * zubrod performance score 0-1. * neurologic function score 0, 1, or 2. * patients receiving glucocorticoids should be tapered to the lowest possible dose, or altogether, as judged by the participating physician. if glucocorticoid dose is adjusted or given for the first time, patient must remain on stable dose of glucocorticoids for at least 3 days prior to initial neurocognitive assessment protocol (nap), ct and mr imaging. exclusion criteria: * major medical illnesses or psychiatric impairments, which in the investigators opinion will prevent administration or completion of the protocol therapy and/or interfere with follow-up. * for patients who have undergone subtotal resection, residual disease must be 4 cm in maximum diameter. * inability to obtain histologic proof of primary malignancy. * patients with leptomeningial metastases documented by mri or cerebral spinal fluid (csf) evaluation.

Keywords: whole brain radiotherapy neural stem cell brain metastases radiosurgery
arthro distension plus intensive mobilisation in shoulder capsulitis

Conditions: Shoulder Capsulitis

Summary: the purpose of this study is to evaluate the effectiveness of arthro distension plus intensive mobilisation in shoulder capsulitis.

the aim of the study is to evaluate a treatment of shoulder capsulitis that associates arthro distension and intensive mobilisation at 2, 6, 12, 26 and 52 weeks. it is a bicentric 87-month (inclusion: 74 months; follow up: 13 months) observer blind randomised clinical trial using 2 groups in parallel. the number of patients to be included is 66. the treatment that is evaluated associates arthro distension followed by mobilisation of the shoulder 6 hours per day during 5 days, and then sessions of physiotherapy for 4 weeks. the control intervention is one intra-articular injection of corticosteroids and physiotherapy. the primary outcome is spadi, namely pain and disability, at 2 weeks.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * shoulder capsulitis * duration of symptoms ≥ 3 months * health insurance exclusion criteria: * cognitive disorders * hypo coagulation * biological inflammatory syndrome * uncontrolled diabetes * xylocaine allergy * pregnancy * unable to understand and to speak french * previous surgery of shoulder * shoulder infiltration or distension in the previous month * local contraindication to shoulder infiltration

Keywords: shoulder capsulitis arthro distension mobilisation randomised clinical trial
the heidelberg engineering anterion corneal epithelium thickness precision and agreement study

Conditions: Normal Cornea; Corneal Abnormality

Summary: this is a prospective clinical study that will be conducted at one clinical site located in the united states to assess corneal epithelial thickness parameters with the anterion


Eligibility criteria:
inclusion criteria: 1. subjects ≥ 22 years of age 2. able and willing to undergo the test procedures, sign informed consent, and follow instructions 3. able to fixate 4. with at least one of the following eye status for the corresponding eye population: * normal cornea * abnormal cornea: eye with at least one of the following a) keratoconus b) contact lens wearer c) status post-keratorefractive surgery (at least 30 days between imaging and keratorefractive surgery) d) dry eye disease exclusion criteria: * exclusion criteria general 1. active infection in either eye 2. insufficient corneal reflex, in the study eye 3. physical inability to be properly positioned at the study devices or eye exam equipment * exclusion criteria normal cornea group 4. abnormal cornea shape or corneal surgery in the study eye 5. contact lens wear within 3 months prior to imaging in the study eye 6. dry eye disease in the study eye * exclusion criteria abnormal cornea group 4. for keratoconus (a): * contact lenses worn within one hour prior to imaging 5. for contact lens wearer (b): * keratoconus * post-keratorefractive surgery * contact lenses worn within one hour prior to imaging 6. for post-keratorefractive surgery (c): * keratoconus * contact lens wear within 3 months prior to imaging in the study eye 7. for dry eye disease (d): * keratoconus * post-keratorefractive surgery * contact lens wear within 3 months prior to imaging in the study eye
icbt program for caregivers of persons with sci

Conditions: Internet-Delivered Cognitive Behavioural Therapy; Depression; Anxiety; Spinal Cord Injuries; Caregiver Burnout

Summary: spinal cord injuries have a devastating effect on individuals incurring the life changing event; however, the injury can also affect those who are integrally involved in their care. assisting individuals after an sci frequently falls on unpaid, family caregivers. studies have reported that caregivers experienced significantly greater negative outcomes than positives. the most common negative outcome factors were high levels of burden, poor adjustment to role, decreased qol, emotional distress, and strain on relationships. burden of care was also associated with lower levels of functioning of the care recipient, demonstrating the integral relationship between those who provide care and those who receive it. considering their importance in maintaining their care recipient's wellbeing post-injury, caregivers require ongoing support as a central part of the wider healthcare system. numerous caregivers are unprepared to handle the responsibilities of their role and lack specialized training to efficiently cope with the burden. guided internet-delivered cbt (icbt) offers an accessible and flexible approach for psychosocial service delivery in the community. evidence for the effectiveness of icbt has been reported in various populations. the results from our study provide evidence for the potential of guided icbt to improve psychosocial outcomes among those with sci. enhancing the overall wellbeing of the caregiver has previously been shown to improve outcomes of those with sci. however, evidence for the acceptability and effectiveness of an icbt approach among caregivers is lacking; as a first step, we plan to conduct a feasibility study of icbt for sci caregivers.


Eligibility criteria:
inclusion criteria: 1. adults ≥ 18 years 2. have provided care to a person with sci in the community for a period of over six months post injury 3. report elevated symptoms of anxiety and/or depression 4. access to a computer and the internet 5. cognitive capacity to read and understand the content of the intervention. exclusion criteria: 1. high risk of suicide 2. primary problems with psychosis, alcohol or drug problems, mania 3. currently receiving active psychological treatment for anxiety or depression 4. concerns about online therapy.
phase 4 study of effect of aspirin on flushing in dimethyl fumarate-treated participants with relapsing-remitting multiple sclerosis

Conditions: Relapsing-Remitting Multiple Sclerosis

Summary: the primary objective of the study is to evaluate whether 150 mg enteric-coated aspirin (acetylsalicylic acid \[asa\]) taken twice a day (bid) with dimethyl fumarate (dmf) administration or 75 mg enteric-coated asa taken once daily in the morning (qam) with dmf administration reduces the incidence and/or severity of flushing events in subjects with relapsing-remitting multiple sclerosis (rrms) compared with asa-placebo administered with dmf in the clinical practice setting. secondary objectives of this study are: to evaluate the safety and tolerability of dmf administered with and without enteric-coated asa in the clinical practice setting; to evaluate the impact of dmf administration on quality of life as measured by the short form 36 (sf-36®) and european quality of life - 5 dimensions - 5 levels (eq-5d-5l) questionnaires.


Eligibility criteria:
key inclusion criteria: * naïve to fumaric acid esters (e.g. dmf, fumaderm, compounded fumarates) * diagnosed with rrms and satisfies the approved therapeutic indication for dmf * participants of childbearing potential must practice effective contraception and be willing and able to continue contraception throughout the study * ability to complete the tolerability scales accurately using the electronic diary (ediary) and ability to complete the paper flushing diaries key exclusion criteria: * inability or unwillingness to comply with study requirements or, at the discretion of the investigator, is deemed unsuitable for study participation * one or more major comorbidities that, in the opinion of the investigator, may affect the outcome of the study or otherwise makes the subject an unsuitable candidate for study participation. the prevailing product labels for both dmf and asa should be used as guides * known active malignancies (subjects with cutaneous basal cell carcinoma that has been completely excised prior to study entry remain eligible) * chronic use (≥7 consecutive days) of asa- or nonsteroidal anti-inflammatory drugs (nsaid)-containing products within the month prior to enrollment in the study * a known intolerance to asa * active peptic ulceration or a history of peptic ulceration, hemophilia or other clotting disorders, or gout * known hypersensitivity reactions (e.g., bronchospasm, rhinitis, urticaria) in response to asa or nsaid administration * impaired hepatic or renal function, in the opinion of the investigator * female subject is pregnant, lactating, or will be attempting to become pregnant during the double-blind period (first 12 weeks) of the study * currently participating in another interventional clinical trial note: other protocol-defined inclusion/exclusion criteria may apply

Keywords: multiple sclerosis flushing aspirin
evaluation of gastrointestinal transit pre and pos treatment with non selective betablocker in a population of cirrhotics

Conditions: Liver Cirrhosis

Summary: the purpose of this study is to evaluate the influence of non betablockers in gastrointestinal motility (transit time) in patients with liver cirrhosis.

there is some evidence that cirrhotic patients have increased gastrointestinal transit time, this issue may favor bacterial owergrowth, and consequently bacterial translocation. translocation of bacterias and its products are linked to vascular and hemodynamics alterations that produce descompensation on the disease. there is evidence , in animal models , that the use of beta blockers favors the gastrointestinal movement; decompensated cirrhotics had significantly longer small bowel transit time as compared with compensated cirrhotics, there have described that this alteration is related to de cirrhosis severity as assessed by child pugh score. the purpose of this study is to evaluate the gastrointestinal transit time before and after treatment of non selective betablockers, we are going to evaluate the gastrointestinal time before and after of 4 weeks of non selectivebetablocker treatment, in decompensated cirrhotics. the gastrointestinal time is going to be evaluate by the ingestion of a device known as "smart pill", that allow ambulatory monitoring of gastrointestinal transit.

Eligibility criteria:
inclusion criteria: * cirrhosis of any ethiology * child pugh a, b, c without beta-blocker treatment previously (min. 1 month without treatment) * patients with previous variceal bleeding (with liver cirrhosis) \* patients with ascites or bacterial spontaneous peritonitis exclusion criteria: * variceal disease without cirrhosis * cirrhotics patients that use antibiotics, prebiotics and probiotics during the study period and one month previously * patients under immunosuppressor treatment * patients with portal thrombosis * patients with sd. budd-chiari or cava/suprahepatic thrombosis * patients with active infection process

Keywords: liver cirrhosis variceal bleeding non selective beta blockers
the role of canine fossa trephination in the severely diseased maxillary sinus

Conditions: Disorder of Maxillary Sinus; Aspirin-sensitive Asthma With Nasal Polyps; Rhinosinusitis

Summary: the hypothesis of this study is that canine fossa trephination (cft) improves surgical outcomes for patients with a severely diseased maxillary sinus.

chronic sinusitis (crs) with nasal polyps and thick mucin in the sinuses adversely affects results from endoscopic sinus surgery (ess) because failure to clear the disease leads to ongoing inflammation and symptoms. in particular a subset of crs patients with thick eosinophilic mucin (emcrs) develop recurrent symptoms and require further surgeries. ess techniques for the maxillary sinus requires a wma in the side wall of the sinus and the use of curved debrider instruments to clear the polyps. sometimes this doesn't provide access to the inferior/floor and anterior/front aspects of the maxillary sinus due to the fact that the maxillary sinus is on the side of the nasal cavity at an angle. the cft through the front wall of the sinus was developed years ago as an alternative approach to improve access to these areas. both techniques are acceptable standard treatments and which one is initially used to address the maxillary sinus currently depends on surgeon preference. the role of cft has been studied by sathanatar et al (laryngoscope 2005) and lee et al (laryngoscope 2008) which provided conflicting results. differences in their study patients and methodology could explain the different outcomes. hence this study is proposed to clarify the role of cft in patients with extensive maxillary sinus disease to see whether initial use of cft is more helpful than wma in the severely diseased maxillary sinus with polyps and mucin. findings from this study may improve surgical outcomes for crs patients in the future.

Eligibility criteria:
inclusion criteria: * patients with extensively opacified maxillary sinuses on ct scanning undergoing endoscopic sinus surgery for chronic rhinosinusitis * patients with eosinophilic mucin chronic rhinosinusitis or fungal sinusitis disease undergoing endoscopic sinus surgery for chronic rhinosinusitis * patients with recalcitrant chronic rhinosinusitis undergoing endoscopic sinus surgery for chronic rhinosinusitis * patients over the age of 18 * patients able to give informed consent to participate in the study exclusion criteria: * patients will be excluded if they are unable to undergo surgery due to co morbidities. * patients with previous caldwell-luc procedures * patients with pre existing paraesthesia of the upper teeth or gums * patients with destructive lesions of the maxilla * patients with systemic disease affecting the paranasal sinuses (e.g. wegener's granulomatosis) * patients immune compromised

Keywords: chronic rhinosinusitis canine fossa trephine canine fossa puncture